SCHEMBL2169903

SCHEMBL2169903

CCOC(=O)C(C)ON=Cc1cc(Br)c(Oc2ccc(OC)c(-c3ccccc3)c2)c(Br)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
LMNA P02545 4/20 0.42
TNFRSF1A P19438 1/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
PKM P14618 1/20 0.37
APP P05067 1/20 0.37
PPARG P37231 2/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 2/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTT P42858 1/20 0.36
PRNP P04156 1/20 0.36
GAA P10253 1/20 0.36
ALOX12 P18054 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16496686 1.00 MAPT (0.42) MAPTLMNATNFRSF1AALDH1A1HPGD
SCHEMBL16496323 0.91 MAPT (0.41) MAPTLMNATNFRSF1AALDH1A1HPGD
SCHEMBL2183907 0.91 MAPT (0.41) MAPTLMNATNFRSF1AALDH1A1HPGD
SCHEMBL2827033 0.91 TNFRSF1A (0.38) MAPTLMNATNFRSF1AALDH1A1HPGD
SCHEMBL2827035 0.91 TNFRSF1A (0.38) MAPTLMNATNFRSF1AALDH1A1HPGD
SCHEMBL2233640 0.86 LMNA (0.40) MAPTLMNATNFRSF1AALDH1A1HPGD
SCHEMBL16495869 0.86 LMNA (0.42) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2187070 0.86 LMNA (0.42) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2233635 0.86 LMNA (0.40) MAPTLMNATNFRSF1AALDH1A1HPGD
SCHEMBL2170701 0.86 TNFRSF1A (0.40) MAPTLMNATNFRSF1AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US claimed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP claimed
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US disclosed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP disclosed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301200-A1 THYROID RECEPTOR LIGANDS TSHR, THRB, THRA MAPT 692/4885LMNA 3227/4885TNFRSF1A 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.